Technical Analysis for AKTX - Akari Therapeutics Plc

Grade Last Price % Change Price Change
grade D 2.63 -4.71% -0.13
AKTX closed down 4.71 percent on Monday, May 20, 2019, on 3 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical AKTX trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion -4.71%
Down 3 Days in a Row Weakness -4.71%
Lower Bollinger Band Touch Weakness -4.71%

Older signals for AKTX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company develops Coversin, a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b – 9 (membrane attack complex or MAC). It develops products to treat rare diseases, such as paroxysmal nocturnal haemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), myasthenia gravis (MG), Guillain Barré syndrome (GBS), and Sjögren's syndrome. The company was formerly known as Volution Immuno Pharmaceuticals SA and changed its name to Akari Therapeutics, Plc in September 2015. The company is based in New York, New York. Akari Therapeutics, Plc operates as a subsidiary of RPC Pharma Limited.
Medicine Biopharmaceutical Medical Specialties Organ Systems Rare Diseases Autoimmunity Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Myasthenia Gravis Alexion Pharmaceuticals Atypical Hemolytic Uremic Syndrome Complement System
Is AKTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.2
52 Week Low 1.56
Average Volume 3,071,000
200-Day Moving Average 2.2962
50-Day Moving Average 3.5122
20-Day Moving Average 3.396
10-Day Moving Average 3.083
Average True Range 0.2984
ADX 21.21
+DI 21.9231
-DI 29.3665
Chandelier Exit (Long, 3 ATRs ) 4.1448
Chandelier Exit (Short, 3 ATRs ) 3.5052
Upper Bollinger Band 4.1615
Lower Bollinger Band 2.6305
Percent B (%b) 0.0
BandWidth 45.08245
MACD Line -0.152
MACD Signal Line -0.0506
MACD Histogram -0.1014
Fundamentals Value
Market Cap 30.97 Million
Num Shares 11.8 Million
EPS -2.00
Price-to-Earnings (P/E) Ratio -1.32
Price-to-Sales 0.00
Price-to-Book 2.11
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.90
Resistance 3 (R3) 2.92 2.86 2.86
Resistance 2 (R2) 2.86 2.79 2.85 2.84
Resistance 1 (R1) 2.74 2.75 2.71 2.72 2.82
Pivot Point 2.68 2.68 2.66 2.67 2.68
Support 1 (S1) 2.56 2.61 2.53 2.54 2.44
Support 2 (S2) 2.50 2.57 2.49 2.42
Support 3 (S3) 2.38 2.50 2.41
Support 4 (S4) 2.36